COMMUNIQUÉS West-GlobeNewswire

PerfectServe Ranks #1 Across All Use Cases in the Gartner® Critical Capabilities for Clinical Communication and Collaboration Report
22/04/2026
Following recognition as highest in execution and furthest in vision in the 2026 Magic Quadrant™ for Clinical Communication and Collaboration MIAMI, April 22, 2026 (GLOBE NEWSWIRE) -- PerfectServe®, a leading provider [...]
LIfT BioSciences Announces Publication of Review Article in Frontiers in Immunology Highlighting Broad Therapeutic Potential of Neutrophils and IMANs in Cancer
22/04/2026
Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease context LIfT BioSciences’ immunomodulatory alpha [...]
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
22/04/2026
Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product production GLEN ALLEN, Va [...]
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
22/04/2026
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia HOUSTON, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq [...]
Three-Peat: Becker’s Healthcare Dubs U.S. Oral Surgery Management a DSO to Know
22/04/2026
IRVING, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- For the third year in a row, Becker’s Healthcare has named U.S. Oral Surgery Management ( USOSM ) to its annual DSOs to Know list. Honorees are selected by Becker’s, [...]
NETRIS Pharma: Nature publishes positive pancreatic cancer Phase 1b data for NP137 anti-netrin-1 monoclonal antibody
22/04/2026
LAPNET-01 Phase 1b study shows netrin-1 blockade may overcome and prevent chemoresistance in patients with pancreatic ductal adenocarcinoma (PDAC) with locally advanced PDAC (LAPC) NP137 is the first-in-class anti- [...]
Neurona Presents Updated Data from Ongoing Clinical Trials of Rezanecel (NRTX-1001) Regenerative Cell Therapy in Mesial Temporal Lobe Epilepsy at 2026 American Academy of Neurology (AAN) Annual Meeting
22/04/2026
- UNILATERAL MTLE: Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy evaluation period (N=9), and 100% median disabling seizure reduction in [...]
Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at Eyecelerator @ ARVO 2026
22/04/2026
MKIs uniquely block multiple receptor tyrosine kinases (RTKs) simultaneously, addressing the inflammatory, vascular, and fibrotic causes of serious, underserved front-of-the-eye diseases Lead MKI candidates, CBT-001 and [...]
MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
22/04/2026
MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March [...]
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
22/04/2026
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of Hematology (ASH) Annual [...]
Astiva Health Entered April 2026 with Record High 47,000+ Enrolled Members
22/04/2026
ORANGE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Astiva Health (“Astiva” or the “Company”), a rapidly growing Medicare Advantage organization serving California’s diverse senior population, today announced another [...]
The Beauty Health Company Announces Corporate Rebrand to SkinHealth Systems, Reflecting Evolution into a Clinically Driven, Science-Backed Medical Aesthetics Platform
22/04/2026
The Company will continue trading on the Nasdaq Capital Market under the ticker symbol “SKIN” LONG BEACH, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) today announced a corporate [...]
PMV Pharmaceuticals Announces Board Chair Transition
22/04/2026
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “ [...]
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
22/04/2026
CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the [...]
SRx Health Solutions Invests in Astro Investment XVII, an Affiliate of Astro Capital
22/04/2026
Company has invested greater than 10% of its investable capital in the convergence of Artificial Intelligence (“AI”) and space through Astro Capital NORTH PALM BEACH, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- SRx Health [...]
Accent Trial Mature Data Presented at International Conference
22/04/2026
HIGHLIGHTS Mature data from Amplia’s ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meeting The ACCENT trial investigates the combination of [...]
Cue Biopharma Announces 1-for-30 Reverse Stock Split
22/04/2026
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
22/04/2026
Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a therapeutic target [...]
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
22/04/2026
CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]

Pages